Titre :

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT.

Auteur(s) :

Tilmont, Remi [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Yakoub-Agha, Ibrahim [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Lille Inflammation Research International Center - U 995 [LIRIC]
Eikema, Diderik-Jan [Auteur]
Universiteit Leiden = Leiden University
Zinger, Nienke [Auteur]
Leiden University Medical Center [LUMC]
Haenel, Mathias [Auteur]
Chemnitz University of Technology / Technische Universität Chemnitz
Schaap, Nicolaas [Auteur]
Radboud University Medical Center [Nijmegen]
Arroyo, Concepcion Herrera [Auteur]
Hospital Universitario Reina Sofía de Córdoba
Schuermans, Christine [Auteur]
Besemer, Britta [Auteur]
Eberhard Karls Universität Tübingen = University of Tübingen
Engelhardt, Monika [Auteur]
Universitäts Klinikum Freiburg = University Medical Center Freiburg [Uniklinik]
Kuball, Jürgen [Auteur]
University Medical Center [Utrecht] [UMCU]
Michieli, Mariagrazia [Auteur]
Schub, Natalie [Auteur]
University Medical Center of Schleswig–Holstein = Universitätsklinikum Schleswig-Holstein [UKSH]
Wilson, Keith M. O. [Auteur]
Cardiff University
Bourhis, Jean-Henri [Auteur]
Institut Gustave Roussy [IGR]
Mateos, Maria Victoria [Auteur]
Universidad de Salamanca [España] = University of Salamanca [Spain]
Rabin, Neil [Auteur]
University College London Hospitals [UCLH]
Jost, Edgar [Auteur]
Universitätsklinikum RWTH Aachen - University Hospital Aachen [Aachen, Germany] [UKA]
Kröger, Nicolaus [Auteur]
University Hospital Hamburg-Eppendorf
Moraleda, José M. [Auteur]
Hospital Clínico Universitario Virgen de la Arrixaca = University Hospital Virgen de la Arrixaca [Murcia]
Za, Tommaso [Auteur]
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hayden, Patrick J. [Auteur]
Trinity College Dublin
Beksac, Meral [Auteur]
Ankara University School of Medicine [Turkey]
Mclornan, Donal P. [Auteur]
University College London Hospitals NHS Foundation Trust [London, UK] [UCLH]
Schönland, Stefan [Auteur]
Heidelberg University Hospital [Heidelberg]
Manier, Salomon [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]

Titre de la revue :

BONE MARROW TRANSPLANTATION

Éditeur :

Nature Publishing Group

Date de publication :

2023-08-07

ISSN :

0268-3369

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

In the setting of a first relapse of multiple myeloma (MM), a second autologous stem cell transplant (ASCT) following carfilzomib-lenalidomide-dexamethasone (KRd) is an option, although there is scarce data concerning this ...
Lire la suite >In the setting of a first relapse of multiple myeloma (MM), a second autologous stem cell transplant (ASCT) following carfilzomib-lenalidomide-dexamethasone (KRd) is an option, although there is scarce data concerning this approach. We performed a retrospective study involving 22 EBMT-affiliated centers. Eligible MM patients had received a second-line treatment with KRd induction followed by a second ASCT between 2016 and 2018. Primary objective was to estimate progression-free survival (PFS) and overall survival (OS). Secondary objectives were to assess the response rate and identify significant variables affecting PFS and OS. Fifty-one patients were identified, with a median age of 62 years. Median PFS after ASCT was 29.5 months while 24- and 36-months OS rates were 92.1% and 84.5%, respectively. Variables affecting PFS were an interval over four years between transplants and the achievement of a very good partial response (VGPR) or better before the relapse ASCT. Our study suggests that a relapse treatment with ASCT after KRd induction is an effective strategy for patients with a lenalidomide-sensitive first relapse. Patients with at least four years of remission after a frontline ASCT and who achieved at least a VGPR after KRd induction appear to benefit the most from this approach.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL